|
A Phase I Trial of CCL-21 Gene Modified DC in NSCLC
|
5R21CA105705-02
|
$331,634
|
$331,634
|
Dubinett, Steven
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Ad5-TRIAL gene therapy for prostate cancer
|
5R21CA110486-02
|
$122,982
|
$122,982
|
Williams, Richard
|
UNIVERSITY OF IOWA
|
|
Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
|
5R21CA117131-02
|
$286,141
|
$71,535
|
Press, Oliver
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Anti-Idiotype Therapy of Human B Cell Malignancy
|
5R37CA033399-26
|
$594,988
|
$297,494
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
$4,800
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Biology & Transplantation of the Human Stem Cell
|
5P01CA065493-13
|
$2,065,942
|
$1,032,971
|
MCGLAVE, PHILIP
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Cancer and Leukemia Group B
|
5U10CA032291-26
|
$333,194
|
$23,324
|
WINER, ERIC
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
5U10CA047577-20
|
$160,142
|
$11,210
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Cancer and Leukemia Group B
|
5U10CA077597-10
|
$113,805
|
$7,966
|
Liu, Minetta
|
GEORGETOWN UNIVERSITY
|
|
CANCER AND LEUKEMIA GROUP B
|
5U10CA077651-10
|
$264,314
|
$18,502
|
Hudis, Clifford
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Cancer and Leukemia Group B
|
5U10CA041287-22
|
$266,860
|
$18,680
|
FLEMING, GINI
|
UNIVERSITY OF CHICAGO
|
|
Cancer and Leukemia Group B
|
3U10CA031946-26S2
|
$450,000
|
$31,500
|
SCHILSKY, RICHARD
|
UNIVERSITY OF CHICAGO
|
|
Cancer and Leukemia Group B
|
5U10CA031946-26
|
$10,080,981
|
$705,669
|
SCHILSKY, RICHARD
|
UNIVERSITY OF CHICAGO
|
|
Cancer and Leukemia Group B
|
5U10CA037447-24
|
$1,615,920
|
$64,637
|
SCHILSKY, RICHARD
|
UNIVERSITY OF CHICAGO
|
|
Cancer and Leukemia Group B
|
5U10CA047559-17
|
$118,078
|
$8,265
|
SHEA, THOMAS
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Cancer and Leukemia Group B
|
5U10CA003927-50
|
$247,998
|
$17,360
|
HURD, DAVID
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Cancer and Leukemia Group B - The Ohio State University
|
5U10CA077658-10
|
$434,962
|
$30,447
|
BLOOMFIELD, CLARA
|
OHIO STATE UNIVERSITY
|
|
Cancer and Leukemia Group B Statistical Center
|
5U10CA033601-28
|
$5,064,881
|
$354,542
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
Cancer and Leukemia Group B-Leukemia Correlative Science
|
5U10CA101140-05
|
$994,868
|
$69,641
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Cancer and Leukemia Group B: RPCI/SUNYAB
|
5U10CA059518-15
|
$326,269
|
$22,839
|
LEVINE, ELLIS
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-08
|
$3,827,483
|
$765,497
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
1R44CA124032-01A1
|
$101,130
|
$50,565
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical and Laboratory Studies of Malignant Lymphomas
|
5P01CA034233-23
|
$1,662,201
|
$332,440
|
LEVY, RONALD
|
STANFORD UNIVERSITY
|
|
Clinical study of AdV-tk radiogenetherapy for malignant*
|
4R44CA107745-03
|
$788,188
|
$394,094
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical study of GMCI in Pancreatic Cancer
|
5R43CA119847-02
|
$376,666
|
$94,167
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Community Clinical Oncology Program
|
5U10CA035199-24
|
$413,073
|
$4,131
|
Grinblatt, David
|
EVANSTON NORTHWESTERN HEALTHCARE
|
|
Delaware/Christiana Care CCOP
|
2U10CA045418-21
|
$835,003
|
$8,350
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Delaware/Christiana Care CCOP
|
3U10CA045418-21S1
|
$119,011
|
$1,190
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Dendritic Cell-Based Genetic Immunotherapy for Melanoma
|
3R01CA079976-08S2
|
$124,483
|
$93,362
|
ECONOMOU, JAMES
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Developing Nucleic Acid Therapeutics
|
5R01CA101859-05
|
$267,510
|
$133,755
|
Gewirtz, Alan
|
UNIVERSITY OF PENNSYLVANIA
|
|
Early Clinical Trials of New Anti Cancer Agents
|
5U01CA062491-14
|
$558,617
|
$16,759
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Enhanced Adenoviral Vectors for Ovarian Cancer
|
5R01CA090547-04
|
$205,761
|
$102,881
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
EORTC DATA CENTER
|
5U10CA011488-37
|
$417,479
|
$4,175
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Gene Therapy for Brain Tumors
|
3P01CA069246-11S1
|
$40,392
|
$14,137
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Gene Therapy for Brain Tumors
|
5P01CA069246-11
|
$1,357,853
|
$475,249
|
HOCHBERG, FRED
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Gene Transfer to Facilitate Dose-Intensification in the Treatment of Pediatric B*
|
5R21CA121578-02
|
$206,823
|
$206,823
|
Wagner, Lars
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Genetic Approaches to Cancer Immunotherapy
|
5P01CA059350-14
|
$1,984,035
|
$1,091,219
|
SADELAIN, MICHEL
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM
|
5U10CA035178-24
|
$936,039
|
$9,360
|
Lange, Marianne
|
SPECTRUM HEALTH HOSPITALS
|
|
Greenville SC CCOP
|
2U10CA067663-12
|
$740,000
|
$7,400
|
GIGUERE, JEFFREY
|
ONCOLOGY & HEMATOLOGY ASSOCIATES OF SC
|
|
Greenville SC CCOP
|
3U10CA067663-12S1
|
$100,000
|
$1,000
|
Giguere, Jeffrey
|
ONCOLOGY & HEMATOLOGY ASSOCIATES OF SC
|
|
Heartland Research Consortium CCOP
|
5U10CA114558-03
|
$704,999
|
$7,050
|
LYSS, ALAN
|
MISSOURI BAPTIST MEDICAL CENTER
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
3P01CA030206-25S1
|
$89,324
|
$17,865
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Hematopoietic Cell Transplantation for Hematologic Malignancies
|
5P01CA030206-25
|
$2,776,839
|
$555,368
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Illinois Oncology Research Association CCOP
|
3U10CA035113-24S1
|
$120,000
|
$1,200
|
KUGLER, JOHN
|
ONCOLOGY-HEMATOLOGY ASSOC-CENTRAL ILL
|
|
Illinois Oncology Research Association CCOP
|
5U10CA035113-24
|
$578,969
|
$5,790
|
KUGLER, JOHN
|
ONCOLOGY-HEMATOLOGY ASSOC-CENTRAL ILL
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-11
|
$1,181,405
|
$590,703
|
Albelda, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Immunotherapy with High Frequency, CEA Specific T Cells
|
5P01CA078673-08
|
$1,766,526
|
$1,766,526
|
LYERLY, HERBERT
|
DUKE UNIVERSITY
|
|
Infectivity Enhanced Virotherapy For Ovarian Cancer
|
1R21CA128222-01
|
$275,500
|
$275,500
|
Alvarez, Ronald
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Intravesical rF-GMCSF and rF-TRICOM in the treatment of advanced bladder cancer
|
5R21CA121589-02
|
$241,207
|
$241,207
|
LATTIME, EDMUND
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Kansas City Clinical Oncology Program CCOP
|
5U10CA035176-24
|
$672,441
|
$6,724
|
Gaur, Rakesh
|
KANSAS CITY CLINICAL ONCOLOGY PROGRAM
|
Total relevant funding to Gene Therapy Clinical Trials for this search: $16,341,118
|